Major Publications in the Critical Care Pharmacotherapy Literature: 2023.

Q4 Medicine
Critical care explorations Pub Date : 2024-10-03 eCollection Date: 2024-10-01 DOI:10.1097/CCE.0000000000001162
Brian Murray, Janhavi Athale, Robert A Balk, Michael L Behal, Judah E Brown, Tyler Chanas, Roxana Dumitru, Dalton C Gifford, Benjamin Hohlfelder, Honey M Jones, Mary Beth F Makic, Michelle S Rausen, Alicia J Sacco, Benjamin J Sines, Payal K Gurnani
{"title":"Major Publications in the Critical Care Pharmacotherapy Literature: 2023.","authors":"Brian Murray, Janhavi Athale, Robert A Balk, Michael L Behal, Judah E Brown, Tyler Chanas, Roxana Dumitru, Dalton C Gifford, Benjamin Hohlfelder, Honey M Jones, Mary Beth F Makic, Michelle S Rausen, Alicia J Sacco, Benjamin J Sines, Payal K Gurnani","doi":"10.1097/CCE.0000000000001162","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to summarize the most significant and impactful publications describing the pharmacotherapeutic care of critically ill patients in 2023.</p><p><strong>Data sources: </strong>PubMed/MEDLINE and the Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update.</p><p><strong>Study selection: </strong>Randomized controlled trials and prospective studies of adult critically ill patients assessing a pharmacotherapeutic intervention and reporting clinical endpoints published between January 1, 2023, and December 31, 2023, were eligible for inclusion in this article.</p><p><strong>Data extraction: </strong>Articles from a systematic search and the Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update were included. An a priori defined three-round modified Delphi process was employed to achieve consensus on the most impactful publications based on the following considerations: 1) overall contribution to scientific knowledge and 2) novelty to the literature.</p><p><strong>Data synthesis: </strong>The systematic search and Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update returned a total of 1202 articles, of which 1164 were excluded. The remaining 38 articles underwent a three-round modified Delphi process. In each round, articles were independently scored based on overall contribution to scientific knowledge and novelty to the literature. Included articles are summarized and their impact discussed. Article topics included hydrocortisone for severe community-acquired pneumonia, inhaled amikacin for prevention of ventilator-associated pneumonia, methylene blue for septic shock, restrictive vs. liberal fluid management for sepsis-induced hypotension, andexanet alfa for major bleeding associated with factor Xa inhibitors, and early administration of four-factor prothrombin complex concentrate in patients with trauma at risk for massive transfusion.</p><p><strong>Conclusions: </strong>This review provides a summary and perspective on the potential impact of the most relevant articles in 2023 describing advances in the pharmacotherapeutic care of critically ill patients.</p>","PeriodicalId":93957,"journal":{"name":"Critical care explorations","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11452093/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical care explorations","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/CCE.0000000000001162","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: We aimed to summarize the most significant and impactful publications describing the pharmacotherapeutic care of critically ill patients in 2023.

Data sources: PubMed/MEDLINE and the Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update.

Study selection: Randomized controlled trials and prospective studies of adult critically ill patients assessing a pharmacotherapeutic intervention and reporting clinical endpoints published between January 1, 2023, and December 31, 2023, were eligible for inclusion in this article.

Data extraction: Articles from a systematic search and the Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update were included. An a priori defined three-round modified Delphi process was employed to achieve consensus on the most impactful publications based on the following considerations: 1) overall contribution to scientific knowledge and 2) novelty to the literature.

Data synthesis: The systematic search and Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update returned a total of 1202 articles, of which 1164 were excluded. The remaining 38 articles underwent a three-round modified Delphi process. In each round, articles were independently scored based on overall contribution to scientific knowledge and novelty to the literature. Included articles are summarized and their impact discussed. Article topics included hydrocortisone for severe community-acquired pneumonia, inhaled amikacin for prevention of ventilator-associated pneumonia, methylene blue for septic shock, restrictive vs. liberal fluid management for sepsis-induced hypotension, andexanet alfa for major bleeding associated with factor Xa inhibitors, and early administration of four-factor prothrombin complex concentrate in patients with trauma at risk for massive transfusion.

Conclusions: This review provides a summary and perspective on the potential impact of the most relevant articles in 2023 describing advances in the pharmacotherapeutic care of critically ill patients.

重症监护药物疗法文献中的主要出版物:2023 年。
目标:我们旨在总结2023年描述重症患者药物治疗的最重要和最有影响力的出版物:研究选择:2023年1月1日至2023年12月31日期间发表的评估药物治疗干预并报告临床终点的成人重症患者随机对照试验和前瞻性研究均可纳入本文:数据提取:纳入系统检索和《临床药学和药理学药物治疗文献更新》中的文章。采用先验定义的三轮改良德尔菲程序,根据以下考虑因素就最具影响力的出版物达成共识:数据综合:系统检索和临床药学与药理学药物治疗文献更新共检索到 1202 篇文章,其中 1164 篇被排除。剩余的 38 篇文章经过了三轮修改后的德尔菲流程。在每一轮中,根据文章对科学知识的总体贡献和对文献的新颖性进行独立评分。对纳入的文章进行了总结,并讨论了其影响。文章主题包括氢化可的松治疗重症社区获得性肺炎、吸入阿米卡星预防呼吸机相关性肺炎、亚甲蓝治疗脓毒性休克、脓毒症诱发低血压的限制性输液管理与自由输液管理、andexanet alfa治疗与Xa因子抑制剂相关的大出血,以及在有大量输血风险的创伤患者中早期应用四因子凝血酶原复合物浓缩物:本综述总结并展望了 2023 年最相关文章的潜在影响,这些文章描述了重症患者药物治疗护理方面的进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.70
自引率
0.00%
发文量
0
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信